Loading...
Loading...
PIRS| Name | Value |
|---|---|
| Revenues | 19.5M |
| Cost of Revenue | 0.7M |
| Gross Profit | 18.8M |
| Operating Expense | 16.4M |
| Operating I/L | -11.8M |
| Other Income/Expense | 1.1M |
| Interest Income | 0.5M |
| Pretax | -10.8M |
| Income Tax Expense | 14.3M |
| Net Income/Loss | -10.8M |
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of anticalin-based drugs. The company's primary revenue-generating products include PRS-060/AZD1402, a Phase II clinical trial drug targeting IL-4Ra for asthma and inflammatory diseases; PRS-220, an oral inhaled Anticalin protein for idiopathic pulmonary fibrosis; Cinrebafusp alfa for HER2-high and HER2-low expressing gastric cancers; PRS-344/S095012, a bispecific anticalin-antibody fusion protein for immuno-oncology diseases; and PRS-352, a preclinical-stage program for immuno-oncology diseases. Pieris Pharmaceuticals has strategic collaborations and license agreements with leading pharmaceutical companies and research institutions.
